Chronic Lymphocytic Leukemia Articles | Page 3

Duvelisib Improves PFS in Phase III CLL Trial
Duvelisib reduced the risk of disease progression or death by 48% versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
SF3B1 Mutation Associated With Poor Survival in CLL
Researchers in China have concluded that mutation of the SF3B1 gene is “significantly associated” with poorer progression-free survival and overall survival in patients with chronic lymphocytic leukemia.
CD19 CAR T-Cell Therapy Active in Ibrutinib-Refractory CLL
Treatment with CD19 chimeric antigen receptor-modified T-cell therapy induced a high response rate in patients with high-risk, ibrutinib-refractory chronic lymphocytic leukemia.
Combos Explored to Enhance CLL Outcomes
Julio Chavez, MD, discusses the current state of CLL and emerging regimens moving through the pipeline.
Predictive Factors Found for Treatment With FCO in CLL
A mutation on the NOTCH1 gene was shown to be an independent predictive factor for the reduced efficacy of ofatumumab (Arzerra), a human monoclonal CD20 antibody, in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Obinutuzumab and Bendamustine Combo Shows Encouraging Activity in Upfront CLL
The anti-CD20 monoclonal antibody obinutuzumab (Gazyva) combined with bendamustine (Treanda; BG) in the frontline setting for patients with chronic lymphocytic leukemia was found to induce high rates of complete response and minimal residual disease negativity with no unexpected safety signals, according to results from a phase II open-label, multicenter study.
Ibrutinib-containing Combination Induced High Rate of Bone Marrow MRD Negativity, 100% ORR in IGHV-Mutated CLL
Patients with IGHV-mutated chronic lymphocytic leukemia had high rates of minimal residual disease-negative status in bone marrow following first-line treatment with a combination of ibrutinib (Imbruvica), fludarabine, cyclophosphamide, and obinutuzumab.
Analysis Shows Response to Ibrutinib in CLL Patients With 11q Deletion
Thomas Kipps, MD, PhD, discusses the details of the integrated analysis from the iwCLL meeting, his ongoing research with ROR1 as a target in chronic lymphocytic leukemia, and pivotal combination studies being conducted with ibrutinib.
Ibrutinib/Venetoclax Yields Dramatic Blood Response in Patients With Relapsed/Refractory CLL
Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.
FDA Approves Subcutaneous Rituximab for Blood Cancers
The FDA has approved subcutaneous rituximab (Rituxan Hycela) for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia.
Publication Bottom Border
Border Publication